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Objectives. Polymyositis (PM) and dermatomyositis (DM) are characterized by impaired muscle function with a majority of
patientsdevelopingsustaineddisability.Theaimofthisstudy wasto evaluatethepatient’s individualpriorities (patientpreference)
of disabilities most important to improve in PM/DM using the MacMaster Toronto Arthritis Patient Preference Disability
Questionnaire (MACTAR), to correlate the MACTAR to myositis outcomes and to evaluate its test-retest reliability. Methods.
Twenty-eight patients with PM/DM performed recommended outcomes as well as the MACTAR, which was performed twice
with oneweek apart. Results. Sexual activity, walking,biking, social activities, and sleep constituted the predominating disabilities.
Seventy-two and 33% of the identiﬁed disabilities were not covered by items of the Health Assessment Questionnaire and the
Myositis Activities Proﬁle. Correlations between the MACTAR and health-related quality of life measures were rs = −0.67–0.73,
correlations with measures of activities of daily living and participation in society were rs = 0.51–0.60 with lower correlations for
other outcomes. Intraclass correlation (ICC) and weighted Kappa (Kw)c o e ﬃcients were 0.83 and 0.68, respectively, for test-retest
reliability of the MACTAR. Conclusions. The MACTAR interview had promising measurement properties and identiﬁed patient
preference disabilities in PM/DM that were not covered by recommended outcomes.
1.Introduction
Polymyositis (PM) and dermatomyositis (DM) are chronic
inﬂammatory conditions characterized by muscle weakness,
characteristic skin rashes in DM, and in about 85% of cases
interstitial lung disease [1, 2]. Medical treatment consists
ofhigh-doseglucocorticoids,immunosuppressivetreatment,
and exercise [1, 3]. Although treatment usually results
in diminished muscle inﬂammation and improved muscle
function,themajorityofpatientsdevelopsustaineddisability
[4]. Patients with PM and DM have poorer perceived health
than healthy individuals [5].
The International Myositis Assessment Clinical Study
Group (IMACS) has validated outcome measures for disease
activity and disease damage and recommends the SF-36 to
assess health-related quality of life [6–8]. In addition, two
myositis-speciﬁc outcome measures have been developed
assessing muscle endurance [9] and activities of daily living
[10]. None of these measures reﬂect patient preference.
A patient preference outcome serves to identify indi-
vidual disease-related disabilities. Studies indicate that
predeﬁned outcomes as ﬁxed item questionnaires might
include items not relevant for all patients and might not
include items important to the individual patient [11–
13]. The MacMaster Toronto Arthritis Patient Preference
Disability Questionnaire (MACTAR) is valid and responsive
for patients with rheumatoid arthritis (RA) [11, 14]a n d
systemic sclerosis (SSc) [15, 16].
The objective of this study was to evaluate patient prefer-
ence in PM and DM by use of the MACTAR, to compare the2 ISRN Rheumatology
MACTAR to recommended and disease-speciﬁc outcomes
in PM and DM and to evaluate test-retest reliability of the
MACTAR.
2.Methods
2.1. Patients. Patients with PM/DM are seen annually by
the myositis team at the Rheumatology unit at Karolinska
University Hospital, Stockholm, Sweden; all patients seen
between February 2005 and January 2006 were invited to
participate in the study. Inclusion criteria were (a) diagnosis
of PM or DM according to Bohan and Peter criteria [17],
(b) diagnosis duration > 6 months, and (c) speaking and
understanding the Swedish language. Twenty-nine patients
were invited, of whom one declined participation for
unknown reasons; thus, 28 patients were included. Their
level of education was categorised. Characteristics of all the
28 patients are presented in Table 1.
All patients were given written and oral information and
signed informed consent. The study was approved by the
local ethics committee at the Karolinska University Hospital.
2.2. Assessments. The Dutch modiﬁed MACTAR is a
semistructured interview, including questions on diﬀerent
aspects of disability during the last week, general health,
quality of life, physical function, social function, and
emotional function [14]. In addition the interviewer asks
the patient to identify disabilities due to their PM/DM.
To help the patient to identify disabilities, the interviewer
mentions diﬀerent categories: household work, dressing
and grooming, outdoor activities or activities related to
work, moving around, sexuality, relations, social activities,
recreational activities, sleeping, and maintaining food and
eating habits. The patient ranks the identiﬁed disabilities
in accordance to importance for improvement, and the ﬁve
highest rankeddisabilitiesare recorded.The MACTARvaries
between 19 and 39, where 39 indicates no disability [14].
Measurements of disease activity and disease damage
includes physician’s assessment of global disease activity
(MYOACT Global) and global extraskeletal muscle disease
activity (MYOACT Extra), which includes assessments of
6 organ systems. The myositis damage index global (MDI
Global) includes assessments of 11 organ systems [6–8], and
serum levels of CPK were analysed. The Manual Muscle Test
(MMT) measures isometric strength in 8 muscle groups,
each scored from 0 to 10, with a score varying from 0 to
80 (where 80 indicates full strength). The Health Assessment
Questionnaire (HAQ) comprises 20 questions divided into
8c a t e g o r i e s[ 18]. The HAQ is scored from 0 to 3 (where
3 indicates unable to do). For assessment of Health-Related
Quality of Life (HQL) we used the Short Form 36 questions
(SF-36) comprising of 8 domains. Each SF-36 dimension is
scored from 0 to 100, where 100 is optimal HQL [19].
The Functional Index 2 (FI-2) is a valid disease-speciﬁc
clinical outcome measuring muscle endurance in patients
with PM and DM [9]. It is scored as the number of correctly
performed repetitions in seven muscle groups, ﬁve with a
score varying from 0 to 60 and two with scores varying from
Table 1: Characteristics of 28 PM/DM patients.
Value
Age, years, median (range) 57 (28–74)
Sex, female/male, n 15/13
Diagnosis,PM/DM, n 11/17
Disease duration, years, median (range) 9 (1–32)
Educational level, n (%)
(i) Low 14 (50)
(ii) High 14 (50)
Employment status, n
(i) Part-time/full-time job 18
(ii) Retired 7
(iii) Sick-leave 3
MYOACT Global, VAS, 0–100mm 1 (0–5)b
MYOACT Extra, VAS, 0–100mm 0 (0–6)c
MDI Global VAS, 0–100mm 18 (8–23)c
CPK, µcat/l 1.8 (1.3–2.6)b
FI-2, mean (0–100%) 49 (27–56)b
MMT-8, 0–80 77 (72–80)b
MAP, 1–7 3 (2–4)
HAQ, 0–3.00 0.50 (0.13–1.00)a
MACTAR, 19–39 27 (23–29)
PGA, VAS, 0–100mm 44 (26–59)d
Values are median (quartiles) unless otherwise indicated. aOne missing
case; btwo missing cases: cthree missing cases; done case excluded. Low
educational level; up to and including vocational training, and high
educational level: higher vocational and/or university education. MACTAR:
MacMaster Toronto Arthritis Patient Preference Disability Questionnaire,
MAP: Myositis Activities Proﬁle, FI-2: Functional Index 2, VAS: Visual
Analogue Scale, PGA: patients’ assessment of disease impact on well-being,
HAQ: Health Assessment Questionnaire, MYOACT Global: physician’s
assessmentofglobaldiseaseactivity,MYOACT Extra:physician’sassessment
ofglobal extraskeletalmusclediseaseactivity,MDI Global:myositisdamage
index global, MMT-8: Manuel Muscle Test-in 8 muscle groups, and CPK:
Serum levels of creatine phosphokinase micro cat/litre.
0 to 120 repetitions (60/120 indicating no limitations). The
Myositis Activity Proﬁle (MAP) measures activities of daily
living consisting of 31 items divided into four subscales and
four single items each scored from 1 to 7, 1: “no diﬃculty” to
7: “impossible” [10].
We added a measurement of participation in society
using the patients’ assessment of disease impact on well-
being on a VAS, 0–100 (PGA), where 100 is severe impact
on well-being.
2.3.Experimental Procedures. TheDutchmodiﬁedMACTAR
was ﬁrst translated into Swedish by an authorized trans-
lator and then translated back into Dutch by a bilingual
rheumatologist (RvV), according to the process described by
Guillemin [20]. The translated MACTAR was then reviewed
by three health professionals and pretested for relevance
and comprehension in three patients with PM/DM. During
a visit to the myositis team physical therapists, the FI-2
was performed followed by the MACTAR and the MAP. All
patients with unchanged disease activity and medication forISRN Rheumatology 3
three months were also invited to perform the 15-minute
MACTAR interview once again one week later. All MACTAR
interviews were performed by the same physical therapist
(L. A. Munters) and the FI-2 was performed by any of
two well-trained physical therapists (L. A. Munters or H.
Alexanderson). The team nurse administrated the PGA, the
HAQ, and the SF-36, and any of the two team physicians
assessed myositis damage and disease activity (MDI Global,
MYOACT Global, and MYOACT Extra) and CPK-levels
within a week of the other measurements.
2.4. Statistical Analysis. Analyses of content of the individual
identiﬁed disabilities using the MACTAR were performed
as comparisons to all items in the HAQ and the MAP.
Spearman’s correlation coeﬃcient (rs)w a su s e df o ra n a l y s e s
of correlations between the MACTAR score and the other
measures: rs 0–0.25: “very little or little” correlation, rs 0.26–
0.49: “low”, rs 0.50–0.69: “moderate”, rs 0.70–0.89: “high”,
and rs > 0.90: “very high” correlation [21]. For analyses of
random variation between the test and the retest interview,
the linear Weighted Kappa coeﬃcient (Kw)a n di n t r a c l a s s
correlation coeﬃcient (ICC) were used. The Sign test was
used to analyse systematic variance of the MACTAR score.
ThelevelofsigniﬁcancewasdeterminedtoP<. 05.Weighted
Kappa coeﬃcients between 0 and 0.20 indicate no or low
agreement, between 0.21 and 0.40 as fair, between 0.41 and
0.60 as moderate, between 0.61 and 0.80 as substantial, and
between 0.81 and 1.0 as almost perfect [22]. ICC coeﬃcients
< 0.75 indicate low-fair reliability and those > 0.75 indicate
good-excellent reliability [23]. The disabilities identiﬁed in
the ﬁrst MACTAR interview and at retest were analyzed as
descriptive comparison.
3.Results
3.1. Patient Preference in PM/DM. A total of 43 diﬀerent
disabilities were identiﬁed by using the MACTAR. Eleven
patients identiﬁed sexual activity among the ﬁve disabilities
that were most important to her/him to improve. This was
the most commonly identiﬁed disability followed by walking
(n = 9), social activities (n = 9), sleeping (n = 8), and
bicycling (n = 7). Twenty-one percent of the 43 reported
disabilitieswerecompletelycoveredbyitemsoftheHAQ,7%
were partly covered, and 72% were not covered. Thirty-two
percent were completely covered by items of the MAP, 35%
partly, and 33% were not covered (Table 2).
3.2. Correlations between the MACTAR and Recommended
Outcomes. The MACTAR score correlated best with three
dimensions of the SF-36: mental health (rs =− 0.73) (P<
.05), social functioning (rs =− 0.70) (P<. 05), and role
Emotional (rs =− 0.67) (P<. 05) and secondly with the
PGA (rs = 0.60) (P<. 05).
There were lower correlations to the HAQ (rs =
0.57) (P<. 05), the MAP (rs = 0.51) (P<. 05), the MMT
(rs =− 0.46) (P<. 05), the FI-2 (rs =− 0.29) (NS), the MDI
Global (rs = 0.11) (NS), the MYOACT Global (rs = 0.13)
(NS), the MYOACT Extra (rs = 0.03) (NS), and the CPK
(rs = 0.14) (NS). One patient was excluded due to the
patient’s misunderstanding of the PGA.
3.3. Test-Retest of the MACTAR Score. All 28 patients were
invited to perform retest of the MACTAR. However, in
six cases, the retest interview was not performed due to
administrative problems, one patient declined invitation,
and one patient was excluded due to an emotional crisis.
Therefore, the results are calculated on the remaining 20
patients.
The median MACTAR score was 27 (19–33) for the test
and retest interview. The weighted Kappa coeﬃcient (Kw)
was 0.68 without systematic variation, P = .60. The ICC
was calculated to 0.83 with a measurement error of 3.28
(CV% = 12%). A median of 3 out of 5 (3-4) disabilities
was identical in the MACTAR test and retest; however, they
were not always in the same rank order. A median of 1 (0–
2) disabilities out of ﬁve was ranked identically in the two
MACTAR interviews.
4.Discussion
The MACTAR identiﬁed aspects of disability of high impor-
tance to the patients not covered by IMACS recommended
outcomesandmyositis-speciﬁc outcomes.Thepatientsiden-
tiﬁed sexual activity, walking, biking, social activities, and
sleeping as disabilities deemed most important to improve.
The MACTAR seems to have promising measurement prop-
erties assessing patient preference in these patients.
Most disabilities that were listed by the patients were
not covered by items in the HAQ, while a larger proportion
were covered by items in the MAP. This diﬀerence could be
due to the fact that the MAP is a disease speciﬁc outcome
whereas the HAQ was originally developed for RA. In a
previous study of the Dutch MACTAR in RA only 48% of
the self-reported disabilities were covered by items in the
HAQ which could be due to the fact that the HAQ only
includes self-care and physical activities [14]. Our study
conﬁrms and extends these results to myositis because the
patient-identiﬁed disabilities were also related to restriction
in society and interpersonal interactions and relationships.
The most commonly identiﬁed disability categories by RA
patients in the Dutch study were moving around, household
work, personal care, recreational activities, and hand func-
tionwhichpartlydivergesfromourstudy.InaFrenchpatient
population with systemic sclerosis the most commonly cited
domainsweremobility,domesticlife,andcommunity,social,
and civic life [15]. These variations in prioritized disabilities
m a yb ee x p l a i n e db yt h ed i ﬀerences among the rheumatic
conditionsand/orbypersonalandsocietalcontexts.Strength
of the MACTAR is the possibility to identify disabilities
adapted to the environmental context of importance to the
individual.
Importantly, in our study sexual activity was the most
frequently identiﬁed disability. Limitations in sexual activity
have not to our knowledge been described before in patients
with PM/DM. Questions about sex life are usually excluded
in predeﬁned questionnaires as they can violate personal4 ISRN Rheumatology
Table 2: The highest prioritized MACTAR disabilities identiﬁed by 28 patients with PM/DM and their representation in the HAQ and the
MAP.
MACTAR disabilities na (men/women) Disabilities included in
the HAQ
Disabilities included in
the MAP
Sexual activity 11 (6/5) Not Not
Walks/walking 9 (6/3) Included Included
Social activities 9 (4/5) Not Included
Sleep 8 (2/6) Not Not
Bicycling 7 (2/5) Not Not
Vacuuming 6 (1/5) Included Included
Getting up from
ground/ﬂoor 5 (3/2) Partly Not
Relations to child/spouse 5 (3/2) Not Not
Carpentry 5 (3/2) Not Partly
Gardening 5 (3/2) Not Included
Disabilities identiﬁed by less than ﬁve individuals: driving a car, playing with child/grandchild, carrying/lifting heavy objects, walking uphill, climbing stairs,
running/jogging, skiing (n = 4), opening jars/bottles, liftinga frying pan, holding a dish brush for longer time,putting up curtains, taking down a lamp from
ceiling, washing hair, traveling (n = 3), swallowing/eating, dancing, getting out of a car/boat, putting on socks/shoes, playing golf, working activities, hiking,
g o i n gt ot h em o v i e s / s p o r t se v e n t s( n = 2), doing buttons,stress management,taking up a boat from water, dressing, playing tennis, climbinga ladder, playing
guitar, walking on icy ground, using public transportation, playing soccer, and fatigue (n = 1).
a Number of patients identifying each of the listed disabilities.
Included: exact the same disability identiﬁed with MACTAR is also included in the questionnaires MAP or HAQ, Partly: the identiﬁed disability is partly
represented in the MAP or HAQ, and Not: the disabilityis not at all represented in the MAP or the HAQ.
integrity.The original HAQincludeda ninth domaininclud-
ing questions about sexual activity; however, the authors
stated that a relatively low number of patients responded to
thisquestionanditwaslateronexcluded[24].IntheSwedish
version of HAQ, sexual activity is not included [18]. Maybe
it is easier to answer questions about sexual activity in an
interview than in a predeﬁned questionnaire.
The MACTAR score correlated best with the SF-36
dimensions mental health, social functioning, role emo-
tional, and the PGA. This could be due to that the MACTAR
includes speciﬁc questions on general health, quality of life,
social function, and emotional function.
Our ﬁndings of high correlations with only three
domains of the SF-36 and lower correlations with the
other myositis outcomes indicate that the MACTAR adds
important new aspects of disability not captured in hitherto
recommended outcomes for patients with PM or DM.
A good to excellent test-retest reliability was achieved for
theMACTARscore.Consideringthelargepotentialvariation
of the score, the error of measurement of 3.28 (CV% = 12)
is fairly small. There was a lower agreement than expected
between the disabilities at test and retest. In some cases this
appeared to be due to external changes such as seasonal
weatherchanges.Theseresultspointoutapossiblelimitation
of the MACTAR in that disabilities once prioritized for
improvement may lose relevance over time [11, 16]. Test-
retest was not performed in eight patients. However, the
missing cases did not diﬀerstatistically signiﬁcantly from the
20 patients in the retest group regarding age, disease activity,
diseaseduration,musclefunction,oractivitiesofdailyliving.
The low total number of patients included in this study
is a limitation, and all patients had chronic, stable disease
with low disease activity. However, patients of both gender,
various ages, disability, and education level were included;
thus the external validity of this study seems reasonable for
patients with chronic disease.
In conclusion, the MACTAR identiﬁed disabilities of
high importance to the patients that were not covered by
recommended and disease-speciﬁc outcomes for patients
with PM and DM. The MACTAR has promising measure-
ment properties assessing patient preference in PM and DM
and might therefore be considered as a patient preference
outcome in clinical trials and other clinical settings.
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